Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Comment by StockDudeLolon Nov 29, 2016 11:53am

91 Views

Post# 25527686

RE:RE:RE:RE:Received e-mail from company

SSM0006 wrote: As for the CEO "dumping" shares - please recheck our facts, Carman acquired shares and reinvested into the company, as well as exercised options, which resulted in additional working capital into our treasury, in order to ramp up production.

Aside from multiple typos, this part is worrying. I just checked all the SEDAR filings again for NF, and there is nothing stating that he bought any more shares... The only things there are news releases, and the "early warning" that he was selling off all of the shares. It's worrying that there is no source provided by her to back up what she's saying.

I'm still holding, but this doesn't actually inspire confidence.

Bullboard Posts

Increasing summer travel could see these airline stocks soar